摘要
目的观察资生丸对肝癌患者肝动脉化疗栓塞(TACE)术后不良反应的干预及临床疗效。方法选择2011年6月至2014年5月在温州市中医院肝病科和肿瘤科住院的72例肝癌患者,随机分成治疗组37例和对照组35例,均行TACE治疗和常规对症支持治疗,治疗组予加用资生丸1包,3次/d,连续服用3个月以上,对照组不予中药治疗。计数资料的比较采用χ2检验,计量资料的比较采用t检验。生存率(OS)比较采用Kaplan-Meier方法及Log-rank检验。结果治疗组第一次TACE术后纳呆和腹胀症状与对照组比较差异均有统计学意义(P<0.05);治疗组第二次TACE术后乏力、纳呆和腹胀症状与对照组比较差异均有统计学意义(P<0.05);治疗组第二次TACE术后KPS评分与对照组比较差异有统计学意义(P<0.05);治疗组第一次TACE术后CD3+、CD4+与对照组比较差异有统计学意义(P<0.05),治疗组第二次TACE术后CD3+、CD4+、CD8+和CD4+/CD8+与对照组比较差异均有统计学意义(P<0.05);治疗组中位生存时间为82周,对照组中位生存时间为74周,两组在OS方面差异无统计学意义(P>0.05),但治疗组2年总生存率43.2%与对照组20.0%比较差异有统计学意义(P<0.05)。结论资生丸对肝癌患者TACE术后不良反应疗效较好,可改善患者症状、提高生活质量和调节外周血T细胞亚群作用,并进一步提高2年总生存率。
Objective To investigate the clinical efficacy of Zisheng pills in the treatment of adverse reactions in patients with primary hepa-tocellular carcinoma （HCC）after transcatheter arterial chemoembolization （TACE）.Methods This study included 72 patients with liver cancer hospitalized in the Department of Liver Diseases and Department of Oncology,Wenzhou Hospital of Traditional Chinese Medicine, from June 2011 to May 2014.These cases were randomly divided into treatment group （n=37）and control group （n=35）.All the patients were treated with TACE,as well as conventional symptomatic and supportive treatment.In addition,the treatment group was given Zisheng pills （one bag）three times a day for at least three consecutive months.Comparison of categorical data was made by chi-square test,while comparison of continuous data （expressed as mean ＆#177;SD）was made by t test.Survival comparison was made by Kaplan-Meier method and log-rank test.Results After the first TACE,there were significant differences in poor appetite and abdominal distension between the treatment group and the control group （P〈0.05）;significant differences were also observed in CD3 ＋and CD4 ＋T lymphocytes between the two groups （P〈0.05）.After the second TACE,there were significant differences in postoperative fatigue,poor appetite,and abdominal distension,as well as postoperative Karnofsky score,between the treatment group and the control group （P〈0.05）;significant differences were also found in CD3 ＋,CD4 ＋,and CD8 ＋T lymphocytes and CD4 ＋/CD8 ＋ratio between the two groups （P〈0.05）.The median sur-vival time showed no significant differences between the treatment group and the control group （82 vs 74 weeks,P〉0.05）,but the 2-year overall survival rate was significantly higher in the treatment group than in the control group （43.2% vs 20%,P〈0.05）.Conclusion Zisheng pills have good clinical efficacy in the treatment of adverse reactions in liver cancer patients after TACE,and it can i
出处
《临床肝胆病杂志》
CAS
2015年第1期74-77,共4页
Journal of Clinical Hepatology
关键词
肝肿瘤
资生丸
化学栓塞
治疗性
liver neoplasms
zisheng pill
chemoembolization,therapeutic
